NP202 / Armaron Bio - LARVOL DELTA

Ca2+/Calmodulin-Dependent Protein Kinase II (CaMKII)-Targeted Drug Discovery: Challenges and Strategies. (PubMed, Ageing Res Rev) - "Current CaMKII inhibitors can be classified into the following categories: CaM-binding site blockers (KN62, KN93); ATP-competitive inhibitors (AS105, GS-680, RA306, RA608, SMP-114, NP202, hesperadin); substrate-binding site blockers (AIP, AC3-I, CN21); and pathway-targeted novel modulators (e.g., Athycaltide-1)...Several innovative approaches hold promise for overcoming current limitations, including: activating endogenous degradation of CaMKII by proteolysis-targeting chimeras (PROTACs), applying novel materials such as peptide- or nucleic acid-based agents and CRISPR-Cas9-mediated gene editing approaches, employing tissue-specific delivery systems and engineered drug molecules, and targeting disease-specific signaling pathways. Together, these strategies may pave the way for more precise and effective CaMKII-targeted interventions in aging-associated diseases."

Journal • Review • Targeted Protein Degradation

NP202 treatment improves left ventricular systolic function and attenuates pathological remodelling following chronic myocardial infarction. (PubMed, Life Sci) - "Improved LV function and structural changes observed with NP202 may be mediated through inhibition of inflammatory and apoptotic processes in the MI setting. NP202 could therefore prove a useful addition to standard therapy in patients with post-MI LV dysfunction."

Journal • Cardiovascular • Fibrosis • Immunology • Inflammation • Myocardial Infarction • CASP3 • CCL2

Calcium/Calmodulin-Dependent Protein Kinase II Delta Inhibition and Ventricular Remodeling After Myocardial Infarction: A Randomized Clinical Trial. (PubMed, JAMA Cardiol) - P2 | "To determine whether NP202, an orally active inhibitor of CaMKIId, prevents LV remodeling in patients after anterior STEMI with early residual LV dysfunction...The drug was safe and well tolerated. ClinicalTrials.gov Identifier: NCT02557217."

Clinical • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • CAMK2D